Glycoprotein acetyls 

GlycA is a novel inflammatory marker, that combines the N-acetyl group signals of several acute phase glycoproteins and glycosylated lipoproteins. The molecules contributing to the GlycA signal are alpha-1-acid glycoprotein, alpha-1-antitrypsin, haptoglobin, transferrin, alpha-1-antimymotrypsin, and glycosylated lipoproteins. GlycA rises in inflammatory conditions both due to an increase in the concentration of acute phase glycoproteins and because of changes in their acetylation. The greatest acute phase protein contributor to the GlycA signal is alpha-1-acid glycoprotein. High triglyceride levels can also increase GlycA levels. The changes in GlycA have previously been primarily studied in humans.


Increased concentrations

– Acute inflammation
– Chronic inflammation
– Neoplasia
– Tissue damage
– Conditions affecting the lipid metabolism

Additional information

Yuki, M., Itoh, H. & Takase, K. Serum alpha-1-acid glycoprotein concentration in clinically healthy puppies and adult dogs and in dogs with various diseases. Vet. Clin. Pathol. 39, 65–71 (2010).
Hagman, R. Serum alpha-1-acid glycoprotein concentrations in 26 dogs with pyometra. Vet. Clin. Pathol. 40, 52–59 (2011).
Lowrie, M. et al. The role of acute phase proteins in diagnosis and management of steroid-responsive meningitis arteritis in dogs. Vet. J. 182, 125–130 (2009).
Connelly, M. A., Otvos, J. D., Shalaurova, I., Playford, M. P. & Mehta, N. N. GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk. J. Transl. Med. 15, 219 (2017).
Ritchie, S. C. et al. The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection. Cell Syst. 1, 293–301 (2015).
Ogilvie, G. K., Walters, L. M., Greeley, S. G., Henkel, S. E. & Salman, M. D. Concentration of alpha 1-acid glycoprotein in dogs with malignant neoplasia. J. Am. Vet. Med. Assoc. 203, 1144–1146 (1993).
Hahn, K. A., Freeman, K. P., Barnhill, M. A. & Stephen, E. L. Serum alpha 1-acid glycoprotein concentrations before and after relapse in dogs with lymphoma treated with doxorubicin. J. Am. Vet. Med. Assoc. 214, 1023–1025 (1999).